Photo: Max Gelman for Endpoints News
Bispecifics continue impressive efficacy streak, but companies look to reduce side effects: #ASH23
SAN DIEGO — Bispecific antibodies from Regeneron, Johnson & Johnson, AbbVie and Roche continue to show impressive efficacy in lymphomas and myeloma based on new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.